{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059763","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.742987+00:00","generated_at":"2026-06-08T14:11:31.819227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences Q3 2023 net loss narrows to $8.1M; cash runway through 2025","bullets":["Q3 2023 revenue $13.1M (up from $7.4M YoY); net loss $8.1M ($0.07/share) vs $23.9M ($0.22/share) in Q3 2022.","Cash and equivalents $122.2M; expects runway through end of 2025, sufficient for Phase 1 data for lead in vivo programs.","Completed Imugene deal for azer-cel: $21M upfront plus potential $198M milestones and double-digit royalties.","PBGENE-HBV targeting CTA/IND in 2024; PBGENE-PMM targeting 2025; iECURE-OTC CTA/IND expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059763","json":"https://secwatch.observer/filing/0000950170-23-059763.json","markdown":"https://secwatch.observer/filing/0000950170-23-059763.md","text":"https://secwatch.observer/filing/0000950170-23-059763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023059763/0000950170-23-059763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023059763/dtil-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:11:31.819227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"766dda58d923b5ba591e7930c27cf80542aae95a","claim":"PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023059763/0000950170-23-059763-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}